Production (Stage)
Tiziana Life Sciences Ltd
TLSA
$1.58
$0.2115.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.32M | 3.32M | 1.97M | 1.97M | 2.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.64M | 4.64M | 3.25M | 3.25M | 4.65M |
| Operating Income | -4.64M | -4.64M | -3.25M | -3.25M | -4.65M |
| Income Before Tax | -4.38M | -4.38M | -3.99M | -3.99M | -4.31M |
| Income Tax Expenses | -778.50K | -778.50K | -1.66M | -1.66M | 224.50K |
| Earnings from Continuing Operations | -3.60M | -3.60M | -2.33M | -2.33M | -4.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.60M | -3.60M | -2.33M | -2.33M | -4.54M |
| EBIT | -4.64M | -4.64M | -3.25M | -3.25M | -4.65M |
| EBITDA | -4.64M | -4.64M | -3.25M | -3.25M | -4.64M |
| EPS Basic | -0.03 | -0.03 | -0.02 | -0.02 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.02 | -0.02 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 110.25M | 110.25M | 103.10M | 103.10M | 102.67M |
| Average Diluted Shares Outstanding | 110.25M | 110.25M | 103.10M | 103.10M | 102.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |